Your browser doesn't support javascript.
loading
Repeat cytoreduction with Hyperthermic Intraperitoneal chemotherapy in patients with peritoneal disease: A 5-year retrospective analysis.
Mendes, João; Marques, Sónia; Peyroteo, Mariana; Lobo, Mercês; Sousa, Fernanda; Fernandes, Manuel; Videira, José Flávio; de Sousa, Abreu.
Afiliación
  • Mendes J; Serviço de Cirurgia Geral, Unidade Local de Saúde do Médio Ave, Portugal. Electronic address: 202191@chma.min-saude.pt.
  • Marques S; Serviço de Cirurgia Geral, Unidade Local de Saúde da Lezíria, Portugal.
  • Peyroteo M; Serviço de Oncologia Cirúrgica, Instituto Português de Oncologia do Porto, Portugal.
  • Lobo M; Serviço de Anestesiologia, Instituto Português de Oncologia do Porto, Portugal.
  • Sousa F; Serviço de Oncologia Cirúrgica, Instituto Português de Oncologia do Porto, Portugal.
  • Fernandes M; Serviço de Oncologia Cirúrgica, Instituto Português de Oncologia do Porto, Portugal.
  • Videira JF; Serviço de Oncologia Cirúrgica, Instituto Português de Oncologia do Porto, Portugal.
  • de Sousa A; Serviço de Oncologia Cirúrgica, Instituto Português de Oncologia do Porto, Portugal.
Surg Oncol ; 54: 102078, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38640857
ABSTRACT

BACKGROUND:

Cytoreductive surgery with Hyperthermic Intraperitoneal Chemotherapy (CR-HIPEC) is a locorregional surgical therapy applied in patients with peritoneal-only metastatic disease of primary abdominal malignancies. Integrated in a multimodal treatment, CR-HIPEC is associated with increased overall survival. In cases of peritoneal-site only relapse, it may be carried out more than once.

METHODS:

Patients who received a CR-HIPEC between January 2016 and December 2020 at Instituto Português de Oncologia do Porto, Portugal were included in a unicentric, retrospective, observational study. Short- and long-term outcomes after surgery were analyzed.

RESULTS:

In this period, 259 CR-HIPEC were performed on 248 patients. Of these, 31 were CR-HIPEC repeats, with 6 being the third HIPEC in the same patient. Of the 31 cases, 15 (48.4 %) had an appendicular origin. Mean PCI in re-HIPEC group was 10.6 (SD ± 7.1). No significant differences in baseline characteristics between the first and re-HIPEC groups were found, except for mean PCI, higher in the 1st HIPEC group (p = 0.047). In re-HIPEC group, major complications rate (CT-CAE 3-4) was 12.9 % (n = 4), without postoperative mortality. The 1st and re-HIPEC group had similar morbidity rates and hospitalization time. With a median follow-up time of 44 months, relapse rate after repeat CR-HIPEC was 45.2 % (n = 14), with a mean overall survival (OS) of 68.7 months and 5-year OS of 78 %.

CONCLUSIONS:

Repeat CR-HIPEC is a safe approach with an acceptable complication rate for its complexity, associated with a survival benefit in selected patients. It should be presented as a valid therapeutic option in recurrent peritoneal disease.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Procedimientos Quirúrgicos de Citorreducción / Quimioterapia Intraperitoneal Hipertérmica Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Peritoneales / Procedimientos Quirúrgicos de Citorreducción / Quimioterapia Intraperitoneal Hipertérmica Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Surg Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos